A 61-Year-Old Woman with Transplant-Preferred Newly Diagnosed Multiple Myeloma (NDMM)

Natalie Callander, MD, presents the case of a 61-year-old woman with transplant-preferred newly diagnosed multiple myeloma (NDMM) and offers her initial impressions.

An expert oncologist discusses the role of stem cell transplantation and currently available therapies for the treatment of newly diagnosed multiple myeloma.

Natalie Callander, MD, reviews the results and quality-of-life outcomes from the GRIFFIN trial on Dara-RVd for patients with transplant-eligible NDMM.

Insights on how the subgroup analysis of the MASTER trial informs the role of autologous stem cell transplantation and the use of quadruplet therapy for elderly patients.

Natalie Callander, MD, details findings from her study, evaluating the impact of quadruplet therapy on newly diagnosed patients with high-risk multiple myeloma.

An overview of recent data from the SKylaRK and GMMG-HD7 trials evaluating non-daratumumab-based regimens for patients with transplant-preferred NDMM.

Natalie Callander, MD, offers advice for community oncologists and discusses unmet needs in treating transplant-preferred patients with newly diagnosed MM.